Patent ID: 11931357
Assignee: MAPI PHARMA LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 13:
14. The composition according to claim 1, which provides one or more of the following cariprazine release in an aqueous medium containing 0.1% sodium lauryl sulfate as measured using a dissolution apparatus type II:
(i) less than 20% burst release of the cariprazine or pharmaceutically acceptable salt thereof;
(ii) from about 2% to about 19% burst release of the cariprazine or pharmaceutically acceptable salt thereof;
(iii) less than 40% release of the cariprazine or pharmaceutically acceptable salt thereof within 1 week;
(iv) from about 8% to about 40% release of the cariprazine or pharmaceutically acceptable salt thereof within 1 week;
(v) less than 55% release of the cariprazine or pharmaceutically acceptable salt thereof within 2 weeks;
(vi) from about 15% to about 53% release of the cariprazine or pharmaceutically acceptable salt thereof within 2 weeks;
(vii) less than 80% release of the cariprazine or pharmaceutically acceptable salt thereof within 3 weeks;
(viii) from about 36% to about 71% release of the cariprazine or pharmaceutically acceptable salt thereof within 3 weeks;
(ix) less than 90% release of the cariprazine or pharmaceutically acceptable salt thereof within 4 weeks;
(x) from about 45% to about 86% release of the cariprazine or pharmaceutically acceptable salt thereof within 4 weeks;
(xi) more than 50% release of the cariprazine or pharmaceutically acceptable salt thereof within 5 weeks; and
(xii) from about 62% to about 92% release of the cariprazine or pharmaceutically acceptable salt thereof within 5 weeks.